高カルシウム血症治療市場：タイプ別、エンドユーザー別-2025-2030年の世界予測

高カルシウム血症治療市場は、2023年に195億8,000万米ドルと評価され、2024年には214億1,000万米ドルに達すると予測され、CAGR 10.67％で成長し、2030年には398億3,000万米ドルに達すると予測されています。

高カルシウム血症治療では、副甲状腺機能亢進症、がん、ビタミンDの過剰摂取などの病態に起因することが多い、血中カルシウム濃度の上昇の管理に焦点を当てています。市場範囲には、ビスフォスフォネート、カルシトニン、コルチコステロイドなどの治療薬が含まれ、腎臓結石や心血管障害のような重篤な合併症の軽減に不可欠です。高カルシウム血症の潜在的な重症度から必要性が生じ、病院や外来での日常的な適用が義務付けられています。最終用途の範囲には、主にヘルスケアプロバイダーや専門的な治療を必要とする患者が含まれます。市場は、カルシウム障害に対する意識の高まりとともに、副甲状腺機能亢進症やがんの罹患率の増加によってプラスの影響を受けています。診断方法の技術的進歩や新規治療薬の開発は、成長の触媒として作用します。新たなビジネスチャンスは個別化治療アプローチとバイオシミラー市場にあり、技術革新を活用して特定の患者のニーズに対応します。このような機会を活用するためには、製薬企業とバイオテクノロジー企業との共同研究が推奨されます。しかし、先進治療の高額なコスト、潜在的な副作用、規制上のハードルといった制約が課題となっています。また、未開発地域における認知度の低さも、世界市場への浸透に影響を与えています。これらの課題を克服するためには、ヘルスケア専門家と患者を教育することが最も重要です。費用対効果の高い低侵襲治療の開発におけるイノベーションは、競争上の優位性をもたらす可能性があります。さらに、患者の継続的なモニタリングと管理のためのデジタルヘルスソリューションを模索することで、治療のアドヒアランスとアウトカムを高めることができます。市場情勢はダイナミックであり、臨床イノベーションと規制状況に左右されます。企業は持続的な成長のために、高カルシウム血症の根本的な原因をターゲットとした遺伝子治療のような研究分野に注力すべきです。研究開発努力を新たな動向に合わせ、戦略的パートナーシップを活用することで、企業は市場での地位を高め、世界の足跡を拡大することができます。

市場力学：急速に進化する高カルシウム血症治療市場の主要市場インサイトを公開

高カルシウム血症治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加するがん患者数
  • 高カルシウム血症の患者数の増加
  • 先端技術の登場と高カルシウム血症疾患に対する認識
• 市場抑制要因
  • 高カルシウム血症治療に伴う高コスト
• 市場機会
  • ヘルスケアインフラ改善のための投資の増加
  • 新しい高カルシウム血症治療を実施するための継続的な研究活動
• 市場の課題
  • 高カルシウム血症治療に伴うリスクと合併症

ポーターの5つの力：高カルシウム血症治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：高カルシウム血症治療市場における外部からの影響の把握

外部マクロ環境要因は、高カルシウム血症治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析高カルシウム血症治療市場における競合情勢の把握

高カルシウム血症治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス高カルシウム血症治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、高カルシウム血症治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨高カルシウム血症治療市場における成功への道筋を描く

高カルシウム血症治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがん患者数が増加している
    • 人口における高カルシウム血症の発生率の上昇
    • 先進技術の登場と高カルシウム血症疾患の認知
  • 抑制要因
    • 高カルシウム血症治療に伴う高額な費用
  • 機会
    • ヘルスケアインフラの改善に向けた投資の増加
    • 高カルシウム血症の新たな治療法の実現に向けた継続的な調査活動
  • 課題
    • 高カルシウム血症治療に伴うリスクと合併症
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 高カルシウム血症治療市場：タイプ別

• 医薬品
  • ビスフォスフォネート
  • カルシウム拮抗薬
  • カルシトニン
  • デノスマブ
  • 点滴液と利尿剤
  • プレドニゾン
• 手術

第7章 高カルシウム血症治療市場：エンドユーザー別

• 外来手術センター
• クリニック
• 病院

第8章 南北アメリカの高カルシウム血症治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の高カルシウム血症治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの高カルシウム血症治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Actiza Pharmaceutical Private Limited
• Aetna Inc.
• Alkem Labs
• Amgen, Inc.
• Apotex Inc.
• Aridis Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• Cipla, Inc.
• Crinetics Pharmaceuticals, Inc
• DiaSorin S.p.A.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly & Company
• Glenmark Pharmaceuticals Ltd
• Hikma Pharmaceuticals PLC
• Kyowa Kirin Co., Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Opko Health, Inc.
• Pfizer Inc.
• Rockwell Medical Inc.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceuticals Industries Ltd.
• Torrent Pharmaceuticals Ltd

LIST OF FIGURES

• FIGURE 1. HYPERCALCEMIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. HYPERCALCEMIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. HYPERCALCEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. HYPERCALCEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HYPERCALCEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HYPERCALCEMIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY CALCIMIMETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY IV FLUIDS & DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HYPERCALCEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. CANADA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 50. CHINA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 53. INDIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 105. ITALY HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 117. POLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 120. QATAR HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HYPERCALCEMIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HYPERCALCEMIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM HYPERCALCEMIA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 148. HYPERCALCEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. HYPERCALCEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Hypercalcemia Treatment Market was valued at USD 19.58 billion in 2023, expected to reach USD 21.41 billion in 2024, and is projected to grow at a CAGR of 10.67%, to USD 39.83 billion by 2030.

Hypercalcemia treatment focuses on managing elevated calcium levels in the blood, often resulting from conditions like hyperparathyroidism, cancer, or excessive vitamin D intake. The market scope encompasses therapies such as bisphosphonates, calcitonin, and corticosteroids, which are essential in mitigating severe complications like kidney stones or cardiovascular issues. Necessity arises from hypercalcemia's potential severity, mandating routine application in hospitals and outpatient settings. The end-use scope largely includes healthcare providers and patients requiring specialized care. The market is positively influenced by increasing incidences of hyperparathyroidism and cancer, alongside heightened awareness about calcium disorders. Technological advancements in diagnostic methods and the development of novel therapeutics act as catalysts for growth. Emerging opportunities lie in personalized treatment approaches and the biosimilar market, leveraging technological innovations to cater to specific patient needs. Collaborative research between pharmaceutical companies and biotechnology firms is recommended to exploit these opportunities. However, limitations such as the high cost of advanced treatments, potential side effects, and regulatory hurdles pose challenges. The market also grapples with limited awareness in underdeveloped regions, impacting global market penetration. To overcome these challenges, educating healthcare professionals and patients is paramount. Innovating in the development of cost-effective, minimally invasive therapies could provide competitive advantages. Furthermore, exploring digital health solutions for continuous patient monitoring and management can enhance treatment adherence and outcomes. The nature of the hypercalcemia treatment market is dynamic, driven by clinical innovation and regulatory landscapes. Companies should focus on research areas like gene therapy, targeting the underlying causes of hypercalcemia for sustainable growth. By aligning R&D efforts with emerging trends and leveraging strategic partnerships, businesses can enhance their market position and expand their global footprint.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hypercalcemia Treatment Market

The Hypercalcemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number of cancer patients across the globe
  • Rising incidences of hypercalcemia among population
  • Advent of advanced technologies and awareness of hypercalcemia disorders
• Market Restraints
  • High cost associated with hypercalcemia treatments
• Market Opportunities
  • Increasing investment to improve healthcare infrastructure
  • Ongoing research activities to implement new hypercalcemia treatments
• Market Challenges
  • Risk and complications associated with hypercalcemia treatments

Porter's Five Forces: A Strategic Tool for Navigating the Hypercalcemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hypercalcemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hypercalcemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hypercalcemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hypercalcemia Treatment Market

A detailed market share analysis in the Hypercalcemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hypercalcemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hypercalcemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hypercalcemia Treatment Market

A strategic analysis of the Hypercalcemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypercalcemia Treatment Market, highlighting leading vendors and their innovative profiles. These include Actiza Pharmaceutical Private Limited, Aetna Inc., Alkem Labs, Amgen, Inc., Apotex Inc., Aridis Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Crinetics Pharmaceuticals, Inc, DiaSorin S.p.A., Dr. Reddy's Laboratories Ltd., Eli Lilly & Company, Glenmark Pharmaceuticals Ltd, Hikma Pharmaceuticals PLC, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Opko Health, Inc., Pfizer Inc., Rockwell Medical Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd., and Torrent Pharmaceuticals Ltd.

Market Segmentation & Coverage

This research report categorizes the Hypercalcemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Medications and Surgery. The Medications is further studied across Bisphosphonates, Calcimimetics, Calcitonin, Denosumab, IV Fluids & Diuretics, and Prednisone.
• Based on End-Users, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number of cancer patients across the globe
    • 5.1.1.2. Rising incidences of hypercalcemia among population
    • 5.1.1.3. Advent of advanced technologies and awareness of hypercalcemia disorders
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with hypercalcemia treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investment to improve healthcare infrastructure
    • 5.1.3.2. Ongoing research activities to implement new hypercalcemia treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Risk and complications associated with hypercalcemia treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hypercalcemia Treatment Market, by Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Bisphosphonates
  • 6.2.2. Calcimimetics
  • 6.2.3. Calcitonin
  • 6.2.4. Denosumab
  • 6.2.5. IV Fluids & Diuretics
  • 6.2.6. Prednisone
• 6.3. Surgery

7. Hypercalcemia Treatment Market, by End-Users

• 7.1. Introduction
• 7.2. Ambulatory Surgical Centers
• 7.3. Clinics
• 7.4. Hospitals

8. Americas Hypercalcemia Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Hypercalcemia Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Hypercalcemia Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Actiza Pharmaceutical Private Limited
• 2. Aetna Inc.
• 3. Alkem Labs
• 4. Amgen, Inc.
• 5. Apotex Inc.
• 6. Aridis Pharmaceuticals, Inc.
• 7. Boehringer Ingelheim International GmbH
• 8. Cipla, Inc.
• 9. Crinetics Pharmaceuticals, Inc
• 10. DiaSorin S.p.A.
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Eli Lilly & Company
• 13. Glenmark Pharmaceuticals Ltd
• 14. Hikma Pharmaceuticals PLC
• 15. Kyowa Kirin Co., Ltd.
• 16. Merck & Co., Inc.
• 17. Mylan N.V.
• 18. Novartis AG
• 19. Opko Health, Inc.
• 20. Pfizer Inc.
• 21. Rockwell Medical Inc.
• 22. Sun Pharmaceutical Industries Ltd
• 23. Teva Pharmaceuticals Industries Ltd.
• 24. Torrent Pharmaceuticals Ltd